Huntington's disease
Not recruitingStudy on the Safety and Effects of MBF-015 for Patients with Huntington's Disease
- Disease:Huntington's disease
- Substances:Mbf-015
Spain- Participants:18–64 years
- Substances:Mbf-015
- Sponsor:Medibiofarma S.L.
Rare diseases
Investigational molecules
Locations
Poligono Industrial Mocholi 2 B, Noain C, 31110, Spain
Medibiofarma S.L. is active in clinical research for Huntington’s disease, with interest in treatments aimed at addressing neurological symptoms and disease-related functional decline.
The sponsor’s neurology portfolio reflects a focus on therapeutic options for patients living with inherited neurodegeneration.
Medibiofarma S.L. runs clinical trials in conditions such as Huntington's disease, Crohn's disease, among others.
Clinical trials registered by this sponsor – none is enrolling right now.
Spain
SpainIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.